TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on June 21, 2013. The report discloses the entry into a material definitive agreement regarding the potential issuance of common stock.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the authorization to raise up to $50.0 million in aggregate offering price through an At-the-Market Issuance Sales Agreement.
Material Changes
On June 21, 2013, the Company entered into an agreement with MLV & Co. LLC to act as its sales agent. This agreement allows the Company to sell shares of its common stock in "at-the-market" offerings. The Company will pay MLV a commission of up to 3.0% of the gross proceeds from any shares sold under this agreement.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard terms of the sales agreement. The agreement incorporates customary indemnification rights and expense reimbursements to the sales agent. Sales will be made at market prices, block transactions, or other methods agreed upon by the Company and MLV.
Key Facts for Investor Verification
- The Company has authorized the sale of up to $50.0 million in common stock via an at-the-market facility.
- MLV & Co. LLC is the designated sales agent for this offering.
- The commission rate payable to the agent is up to 3.0% of gross proceeds.
- The agreement is incorporated by reference into the Company's shelf registration statement on Form S-3 (File No. 333-189015).
- No specific financial performance data (revenue, earnings, cash flow) is included in this specific filing.